Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M; Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Aggarwal SP, et al. Among authors: zinman l. Lancet Neurol. 2010 May;9(5):481-8. doi: 10.1016/S1474-4422(10)70068-5. Epub 2010 Apr 1. Lancet Neurol. 2010. PMID: 20363190 Free PMC article. Clinical Trial.
Establishing a Canadian registry of patients with amyotrophic lateral sclerosis.
Korngut L, Genge A, Johnston M, Benstead T, Bourque P, Briemberg H, Casey A, D'Amour M, Dupré N, Figlewicz D, Hader W, Johnston W, Kalra S, Melanson M, O'Connell C, Rouleau G, Shoesmith C, Wee J, Zinman L. Korngut L, et al. Among authors: zinman l. Can J Neurol Sci. 2013 Jan;40(1):29-35. doi: 10.1017/s0317167100012919. Can J Neurol Sci. 2013. PMID: 23250124
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; BENEFIT-ALS Study Group. Shefner JM, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-435. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26982815 Clinical Trial.
Physician-assisted death: A Canada-wide survey of ALS health care providers.
Abrahao A, Downar J, Pinto H, Dupré N, Izenberg A, Kingston W, Korngut L, O'Connell C, Petrescu N, Shoesmith C, Tandon A, Vargas-Santos AB, Zinman L. Abrahao A, et al. Among authors: zinman l. Neurology. 2016 Sep 13;87(11):1152-60. doi: 10.1212/WNL.0000000000002786. Epub 2016 May 13. Neurology. 2016. PMID: 27178703 Free PMC article.
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group. Meininger V, et al. Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28. Lancet Neurol. 2017. PMID: 28139349 Free article. Clinical Trial.
Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.
Patten SA, Aggad D, Martinez J, Tremblay E, Petrillo J, Armstrong GA, La Fontaine A, Maios C, Liao M, Ciura S, Wen XY, Rafuse V, Ichida J, Zinman L, Julien JP, Kabashi E, Robitaille R, Korngut L, Parker JA, Drapeau P. Patten SA, et al. Among authors: zinman l. JCI Insight. 2017 Nov 16;2(22):e97152. doi: 10.1172/jci.insight.97152. eCollection 2017 Nov 16. JCI Insight. 2017. PMID: 29202456 Free PMC article. Clinical Trial.
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
Hodgkinson VL, Lounsberry J, Mirian A, Genge A, Benstead T, Briemberg H, Grant I, Hader W, Johnston WS, Kalra S, Linassi G, Massie R, Melanson M, O'Connell C, Schellenberg K, Shoesmith C, Taylor S, Worley S, Zinman L, Korngut L. Hodgkinson VL, et al. Among authors: zinman l. Can J Neurol Sci. 2018 Nov;45(6):652-659. doi: 10.1017/cjn.2018.311. Can J Neurol Sci. 2018. PMID: 30430962
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group. Shefner JM, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. doi: 10.1080/21678421.2019.1612922. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31081694 Clinical Trial.
261 results